ExploreWatchlistsPricing
  1. JP-listed companies
  2. OncoTherapy Science, Inc.
  3. Financials
  4. Revenue growth (%)

OncoTherapy Science, Inc. (4564)

Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 202522.9-149.59%
Mar 31, 2024-46.2+2736.81%
Mar 31, 2023-1.6-100.66%
Mar 31, 2022247+4705.25%
Mar 31, 20215.1-59.53%
Mar 31, 202012.7-61.30%
Mar 31, 201932.8-224.74%
Mar 31, 2018-26.3-455.54%
Mar 31, 20177.4-111.33%
Mar 31, 2016-65.3+168.34%
Mar 31, 2015-24.3-64.68%
Mar 31, 2014-68.9+45.65%
Mar 31, 2013-47.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat